The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections
Hetero has received the approval from Drug Controller General (India) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.
The product is a generic version of Bristol-Myers Squibb’s brand ‘Daklinza,’ approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment. Research studies indicates that this drug enables the rapid decline of Hepatitis C virus. Daclatasvir is included the World Health Organization’s List of Essential medicines.
- Advertisement -
Comments are closed.